Affimed (NASDAQ:AFMD) Shares Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. raised its holdings in shares of Affimed (NASDAQ:AFMD) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,856 shares of the biopharmaceutical company’s stock after purchasing an additional 15,108 shares during the period. Point72 Asset Management L.P. owned about 2.25% of Affimed worth $1,152,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AFMD. Choreo LLC bought a new stake in shares of Affimed during the 2nd quarter valued at about $54,000. FMR LLC grew its holdings in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Finally, Intellectus Partners LLC raised its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the period. 30.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AFMD. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Finally, Stifel Nicolaus cut their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Down 2.9 %

Shares of AFMD opened at $2.32 on Wednesday. Affimed has a one year low of $2.19 and a one year high of $8.95. The stock’s fifty day moving average is $3.15 and its 200-day moving average is $4.21. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.